The European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Minjuvi (tafasitamab) for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL). The positive opinion was issued by the EMA’s Committee for Medicinal Products for Human Use (CHMP). The opinion is based on data from the Phase III inMIND trial evaluating the […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!